SAB-142 Phase 1 Data Shows C-Peptide Preservation and Improved Glycemic Control in Type 1 Diabetes

summarizeSummary

SAB Biotherapeutics reported positive additional Phase 1 clinical data for its lead Type 1 Diabetes candidate, SAB-142, demonstrating C-peptide preservation and improved glycemic control without increased insulin use.

check_boxKey Events

• Positive Phase 1 T1D Data

  Additional clinical and mechanistic data from the Phase 1 trial of SAB-142 in Type 1 Diabetes patients was presented.

• C-Peptide Preservation

  All four treated T1D participants showed C-peptide preservation, with three exhibiting a "super responder" profile, correlating with T cell exhaustion.

• Improved Glycemic Control

  Participants demonstrated an increase in mean Time in Range (TIR) from 73% at baseline to 85% at Day 120, without an increase in exogenous insulin use.

• Favorable Safety Profile

  The data showed sustained immunomodulation without immunodepletion, with mild, transient adverse events and no drug-related serious adverse events or serum sickness.

auto_awesomeAnalysis

This 8-K filing provides significant positive clinical and mechanistic data from the Phase 1 trial of SAB-142, the company's lead candidate for Type 1 Diabetes. The findings of C-peptide preservation, a "super responder" profile in most participants, and improved glycemic control without increased exogenous insulin use are strong indicators of SAB-142's potential as a disease-modifying therapy. The data also reinforces a favorable safety profile with sustained immunomodulation without immunodepletion, differentiating it from existing treatments. This positive update de-risks the ongoing registrational Phase 2b SAFEGUARD trial and builds confidence in the program's future, which is crucial for a clinical-stage biopharmaceutical company. Investors should monitor the progress of the Phase 2b trial, with topline data expected in 2H 2027.